BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates

  Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2023.

  February 22, 2024

   · 

  21 min read
• Business

  Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

  Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.

  February 22, 2024

   · 

  6 min read
• Drug Development

  Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

  Rhythm Pharmaceuticals, Inc. announced plans to add a cohort of patients with hypothalamic obesity in Japan to its ongoing global Phase 3 clinical trial of setmelanotide, with dosing expected to begin in the third quarter of 2024.

  February 22, 2024

   · 

  9 min read
• Business

  Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

  Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.

  February 22, 2024

   · 

  12 min read
• Drug Development

  Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

  Monopar Therapeutics Inc. today announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program.

  February 22, 2024

   · 

  4 min read
• Business

  Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

  Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.

  February 22, 2024

   · 

  22 min read
• Business

  Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

  Karyopharm Therapeutics Inc. today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024.

  February 22, 2024

   · 

  2 min read
• Business

  MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

  Mind Medicine (MindMed) Inc. announced today that it plans to host a conference call on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.

  February 22, 2024

   · 

  1 min read
• Drug Development

  Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

  Greenwich LifeSciences, Inc. provided the following update on the expansion of the clinical trial into Europe.

  February 22, 2024

   · 

  5 min read
• Biotech Bay

  RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

  RetinalGeniX™ Technologies Inc. announced that it has been granted a patent by the United States Patent and Trademark Office for the Company’s System And Method For Visualization Of Ocular Anatomy.

  February 22, 2024

   · 

  5 min read